Literature DB >> 8032596

Effect of the putative cognitive enhancer, linopirdine (DuP 996), on quantal parameters of acetylcholine release at the frog neuromuscular junction.

S D Provan1, M D Miyamoto.   

Abstract

1. The subcellular mechanism and site of action of linopirdine or DuP 996 (3,3-bis(4-pyridinylmethyl)-1-phenylindolin-2-one) was investigated at the frog neuromuscular junction, using miniature endplate potential (m.e.p.p.) counts and a new method for obtaining unbiased estimates of n (number of functional release sites), p (probability of release), and varsp (spatial variance in p). 2. DuP 996 produced an increase in m (no. of quanta released), which was due to an increase in n and p. The increase in m was concentration-dependent over a range of 0.1-100 microM and completely reversible with 15 min of wash. There was a saturation in the increase in p, but not in the increase in m and n, for [DuP 996] > 10 microM. By contrast, there was no major change in varsp. 3. Block of presynaptic Na(+)- and Ca(2+)-channels with 3 microM tetrodoxin and 1.8 mM Co2+ prevented the m.e.p.p. frequency increase to DuP996, and this effect was completely reversed by washing. 4. Application of the neuronal Ca(2+)-channel blocker, omega-conotoxin GVIA (1 microM) brought about a rapid and profound decrease in the m.e.p.p. frequency increased produced by DuP996. The effect of the toxin was not reversed by prolonged washing. 5. Block of voltage-gated K(+)-channels with 100 microM 4-aminopyridine (4-AP) resulted in only a small (28%) increase in m. The combination of 4-AP (100 microM) and DuP996 (10 microM) produced an increase in m (189%) which was much greater than the sum of the responses to each agent alone. This increase in m was due solely to an increase in n, as p and varsp were unchanged.6. For [DuP 996] up to 100 gM, there was no apparent change in the mean size, amplitude distribution,or time course of m.e.p.ps, signifying that it had no anticholinesterase activity.7. It is concluded that DuP 996 increases the release of quantal transmitter but not the postsynaptic response to the quanta. This appears to involve an effect at the nerve terminal membrane, most likely an increase in Ca2+-conductance, and not an action to block K+-conductance or to release Ca2+ from intraterminal organelles.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032596      PMCID: PMC1910115          DOI: 10.1111/j.1476-5381.1994.tb14858.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  Evoked neurotransmitter release: statistical effects of nonuniformity and nonstationarity.

Authors:  T H Brown; D H Perkel; M W Feldman
Journal:  Proc Natl Acad Sci U S A       Date:  1976-08       Impact factor: 11.205

2.  Facilitatory actions of aminopyridines on neuromuscular transmission [proceedings].

Authors:  W C Bowman; A L Harvey; I G Marshall
Journal:  J Pharm Pharmacol       Date:  1976-12       Impact factor: 3.765

3.  Some properties of conductance changes at the end-plate membrane during the action of acetylcholine.

Authors:  N TAKEUCHI
Journal:  J Physiol       Date:  1963-06       Impact factor: 5.182

4.  Physostigmine, but not neostigmine, inhibits acetylcholine release.

Authors:  M T Alderdice
Journal:  Brain Res       Date:  1979-12-14       Impact factor: 3.252

5.  Stimulation of transmitter release by guanidine derivatives.

Authors:  J M Farley; M I Glavinović; S Watanabe; T Narahashi
Journal:  Neuroscience       Date:  1979       Impact factor: 3.590

6.  Effects of 4-aminopyridine on neuromuscular transmission.

Authors:  H Lundh
Journal:  Brain Res       Date:  1978-09-22       Impact factor: 3.252

7.  Statistical parameters of transmitter release at frog neuromuscular junctions treated with guanidine or tetraethylammonium.

Authors:  R L Volle; D D Branisteanu
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

8.  Effects of 4-aminopyridine at the frog neuromuscular junction.

Authors:  J Molgo; M Lemeignan; P Lechat
Journal:  J Pharmacol Exp Ther       Date:  1977-12       Impact factor: 4.030

9.  The effect of long-term physostigmine administration in Alzheimer's disease.

Authors:  L E Harrell; R Callaway; D Morere; J Falgout
Journal:  Neurology       Date:  1990-09       Impact factor: 9.910

10.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain.

Authors:  P J Whitehouse; D L Price; R G Struble; A W Clark; J T Coyle; M R Delon
Journal:  Science       Date:  1982-03-05       Impact factor: 47.728

View more
  1 in total

1.  Sequence dependence of post-tetanic potentiation after sequential heterosynaptic stimulation in the rat auditory cortex.

Authors:  K Seki; M Kudoh; K Shibuki
Journal:  J Physiol       Date:  2001-06-01       Impact factor: 5.182

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.